Dr. Michael Jarratt, M.D

NPI: 1114909157
Total Payments
$14,645
2017 Payments
$14,645
Companies
2
Transactions
12

Payment Breakdown by Category

Other$10,875 (74.3%)
Research$3,770 (25.7%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,875 9 74.3%
Unspecified $3,770 3 25.7%

Payments by Type

General
$10,875
9 transactions
Research
$3,770
3 transactions

Top Paying Companies

Company Total Records Latest Year
Allergan Inc. $10,875 9 $0 (2017)
Valeant Pharmaceuticals North America LLC $3,770 3 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2017 $14,645 12 Allergan Inc. ($10,875)

All Payment Transactions

12 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
12/05/2017 Allergan Inc. ACZONE DAPSONE GEL 7.5 (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,000.00 General
Category: DERMATOLOGY
09/22/2017 Valeant Pharmaceuticals North America LLC Cash or cash equivalent $2,000.00 Research
Study: A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
08/10/2017 Allergan Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $650.00 General
07/19/2017 Valeant Pharmaceuticals North America LLC Cash or cash equivalent $750.00 Research
Study: A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
06/15/2017 Allergan Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,200.00 General
06/15/2017 Allergan Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $750.00 General
04/25/2017 Allergan Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,000.00 General
03/08/2017 Valeant Pharmaceuticals North America LLC Cash or cash equivalent $1,020.00 Research
Study: Randomized Study Evaluating the Absorption and Systematic Pharmacokinetics of Topically Applied IDP-123 Lotion in Comparison With Tazorac Cream in Subjects With Moderate to Severe Acne Vulgaris Under Maximal Use Conditions
02/23/2017 Allergan Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $650.00 General
01/19/2017 Allergan Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $750.00 General
01/17/2017 Allergan Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,375.00 General
01/17/2017 Allergan Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $500.00 General

Research Studies & Clinical Trials

Study Name Company Amount Records
A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris Valeant Pharmaceuticals North America LLC $2,750 2
Randomized Study Evaluating the Absorption and Systematic Pharmacokinetics of Topically Applied IDP-123 Lotion in Comparison With Tazorac Cream in Subjects With Moderate to Severe Acne Vulgaris Under Maximal Use Conditions Valeant Pharmaceuticals North America LLC $1,020 1

About Dr. Michael Jarratt, M.D

Dr. Michael Jarratt, M.D is a Dermatology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1114909157.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Jarratt, M.D has received a total of $14,645 in payments from pharmaceutical and medical device companies, with $14,645 received in 2017. These payments were reported across 12 transactions from 2 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($10,875).

Practice Information

  • Specialty Dermatology
  • Location Austin, TX
  • Active Since 11/16/2005
  • Last Updated 03/21/2008
  • Taxonomy Code 207N00000X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1114909157

Products in Payments

  • ACZONE DAPSONE GEL 7.5 (Drug) $1,000

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Dermatology Doctors in Austin